sb 203580 has been researched along with Multiple Organ Failure in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biffl, WL; Carnaggio, R; Ciesla, DJ; Johnson, JL; Moore, EE; Silliman, CC | 1 |
Jing, XL; Le, S; Liang, YB; Ma, ZF; Tang, H; Zhan, H | 1 |
2 other study(ies) available for sb 203580 and Multiple Organ Failure
Article | Year |
---|---|
Clinically relevant hypertonicity prevents stored blood- and lipid-mediated delayed neutrophil apoptosis independent of p38 MAPK or caspase-3 activation.
Topics: Apoptosis; Blood Preservation; Caspase 3; Caspase Inhibitors; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Lysophosphatidylcholines; Mitogen-Activated Protein Kinases; Multiple Organ Failure; Neutrophils; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Platelet Activating Factor; Pyridines; Saline Solution, Hypertonic | 2003 |
[Protective effect of p38 mitogen activated protein kinase inhibitor on organs in sepsis in rats].
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Imidazoles; Interleukin-1beta; Male; Multiple Organ Failure; p38 Mitogen-Activated Protein Kinases; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Signal Transduction; Tumor Necrosis Factor-alpha | 2005 |